Order Center

Use the Order Center to build a Shopping Cart, view Saved Shopping Carts, Recent Orders and Quotes

SDS

Search for SDS (Safety Data Sheet) by Product Number

Oligo Ordering

Custom Products and Services, including DNA oligos (Primers and Probes), RNA, siRNA, Peptide Libraries and AQUA Peptides

Redi-Dri™ for Free-Flowing Hygroscopic Powders

Redi-Dri packaging system eliminates clumping typically noted with many hygroscopic powders and provides a free-flowing, ready-to-use material.

Contact Us

Customer Service: 56 2 495 7395

Email Subscription Center

To receive the information that is relevant to your work, explore our subscription center and set your preferences

Lab Start-up programChile 2017-2018

Programa de apoyo a beneficiarios de FONDECYT de Inicio 2015, 2016 y 2017

About Us

Our life science business features a portfolio of more than 300,000 products enabling scientific discovery.

Advanced Structure Search

Copy and paste, advanced query features, instant structure to name generation, element analysis and more

News & Information

Darmstadt, Germany - December 20, 2017 Merck Collaborates with iCON™ to Offer BioReliance® End-to-End Turnkey Modular MAb Manufacturing Platform

Merck today announced a collaboration with IPS-Integrated Project Services, LLC and G-CON Manufacturing, Inc. to provide the most advanced 2,000L monoclonal antibody (MAb) facility and single-use process technology platform.

Read More
Darmstadt, Germany - December 20, 2017 Merck Signs Commercial Supply Agreement with bluebird bio for Viral Vector Manufacturing

Merck today announced that it has signed a commercial supply agreement to manufacture viral vectors for bluebird bio, Inc., of Cambridge, Massachusetts, USA, for its use in potentially transformative gene therapies.

Read More
Darmstadt, Germany - December 19, 2017 Singapore’s IP Office to Grant Merck’s Patent Application for CRISPR Technology

Merck today announced that the Intellectual Property Office of Singapore has issued a “Notice of Eligibility for Grant” for Merck’s patent application covering the company’s CRISPR technology.

Read More